HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Blau syndrome-associated Nod2 mutation alters expression of full-length NOD2 and limits responses to muramyl dipeptide in knock-in mice.

Abstract
The biochemical mechanism by which mutations in nucleotide-binding oligomerization domain containing 2 (NOD2) cause Blau syndrome is unknown. Several studies have examined the effect of mutations associated with Blau syndrome in vitro, but none has looked at the implication of the mutations in vivo. To test the hypothesis that mutated NOD2 causes alterations in signaling pathways downstream of NOD2, we created a Nod2 knock-in mouse carrying the most common mutation seen in Blau syndrome, R314Q (corresponding to R334Q in humans). The endogenous regulatory elements of mouse Nod2 were unaltered. R314Q mice showed reduced cytokine production in response to i.p. and intravitreal muramyl dipeptide (MDP). Macrophages from R314Q mice showed reduced NF-κB and IL-6 responses, blunted phosphorylation of MAPKs, and deficient ubiquitination of receptor-interacting protein 2 in response to MDP. R314Q mice expressed a truncated 80-kDa form of NOD2 that was most likely generated by a posttranslational event because there was no evidence for a stop codon or alternative splicing event. Human macrophages from two patients with Blau syndrome also showed a reduction of both cytokine production and phosphorylation of p38 in response to MDP, indicating that both R314Q mice and cells from patients with Blau syndrome show reduced responses to MDP. These data indicate that the R314Q mutation when studied with the Nod2 endogenous regulatory elements left intact is associated with marked structural and biochemical changes that are significantly different from those observed from studies of the mutation using overexpression, transient transfection systems.
AuthorsJae Dugan, Eric Griffiths, Paige Snow, Holly Rosenzweig, Ellen Lee, Brieanna Brown, Daniel W Carr, Carlos Rose, James Rosenbaum, Michael P Davey
JournalJournal of immunology (Baltimore, Md. : 1950) (J Immunol) Vol. 194 Issue 1 Pg. 349-57 (Jan 01 2015) ISSN: 1550-6606 [Electronic] United States
PMID25429073 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2014 by The American Association of Immunologists, Inc.
Chemical References
  • Interleukin-6
  • NF-kappa B
  • Nod2 Signaling Adaptor Protein
  • Nod2 protein, mouse
  • RNA, Small Interfering
  • Acetylmuramyl-Alanyl-Isoglutamine
  • Receptor-Interacting Protein Serine-Threonine Kinase 2
  • Mitogen-Activated Protein Kinases
  • p38 Mitogen-Activated Protein Kinases
Topics
  • Acetylmuramyl-Alanyl-Isoglutamine (immunology, pharmacology)
  • Animals
  • Arthritis (genetics)
  • Cell Line
  • Gene Knock-In Techniques
  • HEK293 Cells
  • Humans
  • Interleukin-6 (biosynthesis)
  • Macrophages (drug effects, immunology)
  • Mice
  • Mice, Inbred C57BL
  • Mitogen-Activated Protein Kinases (metabolism)
  • Mutation
  • NF-kappa B (biosynthesis)
  • Nod2 Signaling Adaptor Protein (biosynthesis, genetics)
  • Phosphorylation (genetics)
  • Protein Processing, Post-Translational
  • RNA Interference
  • RNA, Small Interfering
  • Receptor-Interacting Protein Serine-Threonine Kinase 2 (metabolism)
  • Sarcoidosis
  • Signal Transduction (genetics)
  • Synovitis (genetics)
  • Ubiquitination
  • Uveitis (genetics)
  • p38 Mitogen-Activated Protein Kinases (metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: